International Parkinson Fonds Germany GmbH Report issue

Foundation Phase 2 Phase 4

Organization Overview

First Clinical Trial
2012
NCT01560754
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

rivastigmine (exelon) (1 trial)

Drugs in Phase 2 Trials (1)

nicotine (nicorette) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hallucinations (Phase 4)

Parkinson Disease (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2